Spectrum Pharmaceuticals (Nasdaq:SPPI) - Aktienkurs, Nachrichten und Analyse

SPPI Aktienübersicht

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	6/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	3/6
Dividenden	0/6

Belohnungen

82.9% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 67.27% pro Jahr

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Analysten sind sich einig, dass der Aktienkurs um 22.3%

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr verwässert

Hat weniger als 1 Jahr Cash Runway

Spectrum Pharmaceuticals, Inc. Wettbewerber

Pyxis Oncology

NasdaqGS:PYXS

US$194.9m

Generation Bio

NasdaqGS:GBIO

US$187.6m

Zentalis Pharmaceuticals

NasdaqGM:ZNTL

US$298.3m

Fennec Pharmaceuticals

NasdaqCM:FENC

US$166.9m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Spectrum Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	US$1.03
52-Wochen-Hoch	US$1.57
52-Wochen-Tief	US$0.32
Beta	2.14
11 Monat Veränderung	4.54%
3 Monate Veränderung	-1.90%
1 Jahr Veränderung	17.05%
33 Jahre Veränderung	-71.39%
5 Jahre Veränderung	-95.10%
Veränderung seit IPO	-99.25%

Aktuelle Nachrichten und Updates

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

Aktionärsrenditen

	SPPI	US Biotechs	US Markt
7D	5.3%	-0.7%	0.04%
1Y	17.0%	10.0%	20.7%

Rendite im Vergleich zur Industrie: SPPI übertraf die Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4 erzielte.

Rendite vs. Markt: SPPI übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is SPPI's price volatile compared to industry and market?
SPPI volatility
SPPI Average Weekly Movement	7.2%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

Stabiler Aktienkurs: SPPIDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: SPPIDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 15% auf 7% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1987	86	Tom Riga	www.sppirx.com

Spectrum Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Spectrum Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
SPPI grundlegende Statistiken
Marktanteil	US$209.89m
Gewinn(TTM)	-US$67.71m
Umsatz(TTM)	US$25.73m

8.2x

Kurs-Umsatz-Verhältnis

-3.1x

Kurs-Gewinn-Verhältnis

Ist SPPI zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
SPPI Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$25.73m
Kosten der Einnahmen	US$2.86m
Bruttogewinn	US$22.87m
Sonstige Ausgaben	US$90.58m
Umsatz	-US$67.71m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.33
Bruttomarge	88.90%
Nettogewinnspanne	-263.16%
Schulden/Eigenkapital-Verhältnis	107.6%

Wie hat sich SPPI auf lange Sicht entwickelt?

Historische Performance und Vergleiche

SPPI Aktienübersicht

Belohnungen

Risikoanalyse

Spectrum Pharmaceuticals, Inc. Wettbewerber

NasdaqGS:PYXS

US$194.9m

NasdaqGS:GBIO

US$187.6m

NasdaqGM:ZNTL

US$298.3m

NasdaqCM:FENC

US$166.9m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Recent updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Price target decreased by 33% to US$1.26

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.17 loss

Price target decreased by 15% to US$2.65

Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

President notifies of intention to sell stock

Consensus revenue estimates increase by 161%

Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022

Spectrum Pharmaceuticals Announces Executive Changes

Forecast to breakeven in 2025

Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc

Spectrum Pharmaceuticals’ ROLVEDON™ Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Consensus revenue estimates increase by 16%

Spectrum Pharmaceuticals, Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Price target decreased to US$3.10

Price target decreased to US$4.13

Spectrum Pharmaceuticals Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Spectrum Pharmaceuticals Announces Commercial Availability of Rolvedon™ (Eflapegrastim-Xnst) Injection

No longer forecast to breakeven

Spectrum Pharmaceuticals, Inc. Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Price target decreased to US$5.40

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Consensus forecasts updated

Spectrum Pharmaceuticals Receives Food and Drug Administration Approval for ROLVEDON (eflapegrastim-xnst) Injection

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Consensus revenue estimates fall by 61%

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Consensus forecasts updated

Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to its Board of Directors

Price target decreased to US$5.60

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Price target decreased to US$5.60

Spectrum Pharmaceuticals: Some Last Words

Spectrum Pharmaceuticals, Inc. Announces Resignation of Kurt Gustafson as Chief Financial Officer

Spectrum Pharmaceuticals, Inc. Announces Acceptance of New Drug Application Filing for Poziotinib

Spectrum Pharmaceuticals Announces Strategic Restructuring

Forecast to breakeven in 2024

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals, Inc. Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at European Society for Medical Oncology Congress 2021

Pomerantz LLP Announces the Filing of Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers

Consensus revenue estimates fall to US$2.30m

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

No longer forecast to breakeven

Price target decreased to US$9.40

High number of new directors

Erträge & Einnahmen